BR112022017425A2 - Usos terapêuticos de compostos macrocíclicos - Google Patents
Usos terapêuticos de compostos macrocíclicosInfo
- Publication number
- BR112022017425A2 BR112022017425A2 BR112022017425A BR112022017425A BR112022017425A2 BR 112022017425 A2 BR112022017425 A2 BR 112022017425A2 BR 112022017425 A BR112022017425 A BR 112022017425A BR 112022017425 A BR112022017425 A BR 112022017425A BR 112022017425 A2 BR112022017425 A2 BR 112022017425A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic uses
- macrocyclic compounds
- compounds
- mammals
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062984159P | 2020-03-02 | 2020-03-02 | |
| PCT/US2021/020255 WO2021178296A1 (en) | 2020-03-02 | 2021-03-01 | Therapeutic uses of macrocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017425A2 true BR112022017425A2 (pt) | 2022-11-29 |
Family
ID=77613771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017425A BR112022017425A2 (pt) | 2020-03-02 | 2021-03-01 | Usos terapêuticos de compostos macrocíclicos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250262216A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4114530A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023515687A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230022151A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115397514A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021229457A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022017425A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174455A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295938A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022010945A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021178296A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111902417B (zh) | 2018-04-25 | 2023-07-28 | 北京普祺医药科技股份有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| WO2022171139A1 (zh) * | 2021-02-10 | 2022-08-18 | 北京国鸿生物医药科技有限公司 | 一种巨环化合物、药物组合物以及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| WO2015112806A2 (en) * | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| BR112018000297A2 (pt) * | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| AU2017302019A1 (en) * | 2016-07-28 | 2019-02-07 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| PT3658148T (pt) * | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
| WO2021063276A1 (zh) * | 2019-09-30 | 2021-04-08 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
-
2021
- 2021-03-01 US US17/905,503 patent/US20250262216A1/en not_active Abandoned
- 2021-03-01 EP EP21764224.8A patent/EP4114530A4/en not_active Withdrawn
- 2021-03-01 CA CA3174455A patent/CA3174455A1/en active Pending
- 2021-03-01 JP JP2022552626A patent/JP2023515687A/ja active Pending
- 2021-03-01 AU AU2021229457A patent/AU2021229457A1/en not_active Abandoned
- 2021-03-01 MX MX2022010945A patent/MX2022010945A/es unknown
- 2021-03-01 KR KR1020227034099A patent/KR20230022151A/ko not_active Ceased
- 2021-03-01 WO PCT/US2021/020255 patent/WO2021178296A1/en not_active Ceased
- 2021-03-01 BR BR112022017425A patent/BR112022017425A2/pt not_active IP Right Cessation
- 2021-03-01 IL IL295938A patent/IL295938A/en unknown
- 2021-03-01 CN CN202180023879.XA patent/CN115397514A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL295938A (en) | 2022-10-01 |
| EP4114530A1 (en) | 2023-01-11 |
| WO2021178296A1 (en) | 2021-09-10 |
| JP2023515687A (ja) | 2023-04-13 |
| AU2021229457A1 (en) | 2022-10-20 |
| CA3174455A1 (en) | 2021-09-10 |
| US20250262216A1 (en) | 2025-08-21 |
| KR20230022151A (ko) | 2023-02-14 |
| EP4114530A4 (en) | 2024-04-17 |
| MX2022010945A (es) | 2022-10-07 |
| CN115397514A (zh) | 2022-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| MX383823B (es) | Macrociclos de diarilo quirales y usos de los mismo. | |
| MX386680B (es) | Polimorfo de macrociclo de diarilo. | |
| CO2021005226A2 (es) | Nuevos compuestos antihelmínticos | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| CL2011003346A1 (es) | Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente. | |
| ECSP056138A (es) | Dihidroquinazolinas sustituidas | |
| BR112015013700A8 (pt) | composição, sequência nucleotídica, anticorpo sintético, e, uso da composição | |
| BRPI0409919A (pt) | combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese | |
| ECSP12012211A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| GT200600240A (es) | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
| BRPI0815708B8 (pt) | composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição | |
| BR112014031394A8 (pt) | Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral | |
| UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
| BR112022023025A2 (pt) | Moduladores de htt para tratar doença de huntington | |
| UY28130A1 (es) | Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso. | |
| EA200701113A1 (ru) | Макролиды | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
| DOP2024000254A (es) | Macrociclos de indazol y su uso | |
| UY39061A (es) | Inhibidores macrocíclicos de rip2-cinasa | |
| CO2026005573A2 (es) | Compuestos heterobifuncionales y métodos de tratamiento de enfermedades | |
| MX2022000082A (es) | Composiciones terapeuticas y metodos para tratar canceres. | |
| CL2022002239A1 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| MX2022010945A (es) | Usos terapeuticos de compuestos macrociclicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2869 DE 30-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |